Alteration of Plasma Antithrombin III Levels in Ischemic Heart Disease

Robert H. Yue; Menard M. Gertler; Toby Starr; Russell Koutrouby

doi:10.1055/s-0038-1647958

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1976; 35(03): 598-606
DOI: 10.1055/s-0038-1647958

Original Article

Schattauer GmbH

Alteration of Plasma Antithrombin III Levels in Ischemic Heart Disease

Authors

Robert H. Yue

¹Cardiovascular Research, Institute of Rehabilitation Medicine New York University Medical Center, New York, New York 10016, U.S.A.
Menard M. Gertler

¹Cardiovascular Research, Institute of Rehabilitation Medicine New York University Medical Center, New York, New York 10016, U.S.A.
Toby Starr

¹Cardiovascular Research, Institute of Rehabilitation Medicine New York University Medical Center, New York, New York 10016, U.S.A.
Russell Koutrouby

¹Cardiovascular Research, Institute of Rehabilitation Medicine New York University Medical Center, New York, New York 10016, U.S.A.

Abstract

Summary

The amount of anti thrombin III in plasma was determined quantitatively in 218 males between 45–60 years of age. The mean antithrombin III value was found to be low in the group with low risk for ischemic heart disease, intermediate in the group with high risk for ischemic heart disease and highest in the group with acute myocardial infarction. Concomitant study of kaolin-activated partial thromboplastin time revealed a sharp decrease in its mean value in the group with acute myocardial infarction. The high correlation between antithrombin III and kaolin-activated partial thromboplastin time for the entire population suggests that the development of ischemic heart disease is a gradual process and that failure of the damping mechanism results as an acute event. These findings may be useful in the determination of the coagulation state of these patients.

Full Text

References

References
1 Abildgaard U. 1969; Binding of Thrombin to Antithrombin III. Scandinavian Journal of Clinical and Laboratory Investigation 24: 23.
2 Alkjaersig N, Fletcher A. P, Sherry S. 1958; The Activation of Human Plasminogen II A Kinetic Study of Activation with Trypsin, Urokinase and Streptokinase. Journal of Biological Chemistry 233: 86.
3 Biggs R, Denson K. W. E, Akman N, Borrett R, Had den M. 1970; Antithrombin III, Antifactor Xa and Heparin. British Journal of Haematology 19: 283.
4 Buluk K, Januszko T, Olbromski J. 1961; Conversion of Fibrin to Desmofibrin. Nature 191: 1093.
5 Celander D. R, Guest M. M. 1955. Euglobulin Lysis Time. In: Tocantins L. M, Kazal L. A. (ed) Blood Coagulation, Hemmorrhage and Thrombosis . Grune and Stratton; New York: P 249.
6 Coleman R. W. 1969; Activation of Plasminogen by Human Kallikrein. Biochemical and Biophysical Research Communication 35: 273.
7 Davie E. W, Ratnoff O. D. 1964; Waterfall Sequence for Intrinsic Blood Clotting. Science 145: 1310.
8 Dombrose F. A, Seegers W. H, Sedensky J. A. 1971; Antithrombin: Inhibition of Thrombin and Autoprothrombin (F-Xa) as a Mutual Depletion System. Thrombosis et Diathesis Haemorrhagica 26: 103.
9 Gertler M. M, Woodbury M. A, Gottsch L. G, White P. D, Rusk H. A. 1959; The candidate for Coronary Heart Disease. Discriminating Power of Biochemical Hereditary and Anthropometric Measurements. Journal of American Medical Association 170: 149.
10 Gertler M. M, Yue R. H, Leetma H. E, Leach C, Starr T. 1973. Alteration of Plasma Antithrombin III Level in Ischemic Heart Disease. Proceedings of IV Congress of the International Society of Thrombosis and Haemostasis, June 19-22 1973. Vienna; Austria:
11 Glueck H, Sherry S, Troll W. 1954; Assay of Plasma Prothrombin with a Synthetic Substrate. Proceedings of the Society of Experimental Biology and Medicine 87: 646.
12 Hedner U, Nilsson I. M. 1973; Antithrombin Illina Clinical Material. Thrombosis Research 3: 631.
13 Highsmith R. F, Rosenberg R. D. 1974; The Inhibition of Human Plasma by Human Antithrombin. Heparin Cofactor Journal of Biological Chemistry 249: 4335.
14 Johnson A. J, Kline D. L, Alkjaersig N. 1969; Assay Methods and Standard Preparations for Plasmin, Plasminogen and Urokinase in Purified Systems, 1967–1968. Thrombosis et Diathesis Haemorrhagica 21: 259.
15 Kaplan A. P, Schreiber A. D, Austen K. F. 1972; Isolation and Reaction Mechanisms of Human Plasma Plasminogen Activator and its Precursor. Federation Proceedings 31: 624 Abs.
16 Lorand L, Konishi K. 1964; Activation of the Fibrin Stabilizing Factor of Plasma by Thrombin. Archives of Biochemistry and Biophysics 105: 58.
17 Lorand L, Konishi K, Jacobsen A. 1962; Transpeptidation Mechanism in Blood Clotting. Nature 194: 1148.
18 MacFarlane R. G. 1964; An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier. Nature 202: 498.
19 Marciniak E, Tsukamura S. 1972; Two Progressive Inhibitors of Factor X a in Human Blood. British Journal of Haematology 22: 341.
20 Niewlarowski S, Prou-Wartelle O. 1959; Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombosis et Diathesis Haemorrhagica 3: 593.
21 Pratt H. W. 1972. Alteration in Plasma Antithrombin III Activity in patients with Myocardial Infarction. Proceedings of the III Congress of the International Society of Thrombosis and Haemostasis, August 22-26 1972. Washington, D. C.:
22 Proctor R. R, Rapaport S. I. 1961; The Partial Thromboplastin Time with Kaolin. American Journal of Clinical Pathology 36: 212.
23 Ratnoff O. D, Menzie C. 1951; A New Method for the Determination of Fibrinogen in Small Sample of Plasma. Journal of Laboratory and Clinical Medicine 37: 316.
24 Rosenberg R. D, Damus P. S. 1973; The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor. Journal of Biological Chemistry 248: 6490.
25 Seegers W. H. 1968; Antithrombin as a Proteinase Inhibitor. Annals of the New York Academy of Science 146: 593.
26 Seegers W. H, Cole E. R, Harmison C. R, Monkhouse F. C. 1964 Neutralization of Autoprothrombin C Activity with Antithrombin Canadian Journal of Biochemistry. 42. 359.
27 Seegers W. H, Marciniak E. 1962; Inhibition of Autoprothrombin C Activity with Plasma. Nature 193: 1188.
28 Soulier J. P, Prou-Wartelle O. 1959; Nouvelles dounees sur les facteurs Hageman et P. T. A., et sur le “contact”. Revue francaise d’estudes cliniques et biologiques 4: 932.
29 Steinbuch M, Blatrix C, Josso F. 1967; α₂-Macroglobulin as a Progressive Antithrombin. Nature 216: 500.
30 Yin E. T, Wessler S, Stoll P. J. 1976; Rabbit Plasma Inhibitor of the Activated Species of Blood Coagulation Factor X. Purification and Some Properties. Journal of Biological Chemistry 246: 3694.
31 Yin E. T, Wessler S, Stoll P. J. 1971; b Biological Properties of the Naturally Occurring Plasma Inhibitor to Activated Factor X. Journal of Biological Chemistry 246: 3703.
32 Yin E. T, Wessler S, Stoll P. J. 1971; c Identity of Plasma-Activated Factor X Inhibitor with Antithrombin III and Heparin Cofactor. Journal of Biological Chemistry 246: 3712.
33 Yue R. H, Starr T, Gertler M. M. 1972. Antithrombin III Levels in Ischemic Thrombotic Vascular Diseases. Proceedings of the HI Congress of the International Society on Thrombosis and Haemostasis, August 22-26 1972. Washington, D. C.:
34 Yue R. H, Starr T, Gertler M. M. 1973; Quantitative Determination of Total Antithrombin III in Plasma. Thrombosis et Diathesis Haemorrhagica 30: 84.
35 Yue R. H, Starr T, Gertler M. M. 1974; The Rivanol Method for the Quantitative Determination of Antithrombin III in Plasma. Thrombosis et Diathesis Haemorrhagica 31: 123.